The isolation of human embryonic stem (ES) cells has fostered development of a potent area of investigation which will impact our understanding of disease mechanisms and has potential to yield effective therapies. These pathogenetic insights and possible treatments may be applied to the various types of muscular dystrophy. This proposal has as its goal the establishment of a Core Facility which will serve as a resource for investigators seeking the causes and cures for these diseases. Two primary services will be offered by this Core: 1) targeting or inactivating genes in human ES cells which cause various forms of muscular dystrophy and 2) in vitro differentiation of these gene targeted cell lines along the skeleteal muscle lineage pathway. Cardiac muscle could also be differentiated. Proof-of-principle experiments will initially target the genes which cause limb-girdle muscular dystrophy 2I (LGMD2I) and fascioscapulohumeral muscular dystrophy (FSHD). Protocols to differentiate skeletal muscle and its precursors will be developed coincident with the gene targeting studies. These latter studies will take advantage of embryoid bodies, derived from cultured human ES cells, which form tissues from all three germ layers. Revealing studies will become possible when gene targeting of muscular dystrophy genes is combined with in vitro differentiation of these cell lines. The ultimate goal of this approach is the provision of cell-based models of disease for development of therapies directed against the diverse forms of muscular dystrophy. The Core Facility proposed herein is envisioned to be a resource which may be utilized by investigators across the country.
| Lee, Angela J; Buckingham, Edward T; Kauer, Aaron J et al. (2018) Descriptive Phenotype of Obsessive Compulsive Symptoms in Males With Duchenne Muscular Dystrophy. J Child Neurol 33:572-579 |
| González Coraspe, José Andrés; Weis, Joachim; Anderson, Mary E et al. (2018) Biochemical and pathological changes result from mutated Caveolin-3 in muscle. Skelet Muscle 8:28 |
| Martinez-Thompson, Jennifer M; Niu, Zhiyv; Tracy, Jennifer A et al. (2018) Autosomal dominant calpainopathy due to heterozygous CAPN3 C.643_663del21. Muscle Nerve 57:679-683 |
| Brun, Brianna N; Willer, Tobias; Darbro, Benjamin W et al. (2018) Uniparental disomy unveils a novel recessive mutation in POMT2. Neuromuscul Disord 28:592-596 |
| Larson, Austin A; Baker 2nd, Peter R; Milev, Miroslav P et al. (2018) TRAPPC11 and GOSR2 mutations associate with hypoglycosylation of ?-dystroglycan and muscular dystrophy. Skelet Muscle 8:17 |
| Carlson, Courtney R; Moore, Steven A; Mathews, Katherine D (2018) Dystrophinopathy muscle biopsies in the genetic testing ERA: One center's data. Muscle Nerve : |
| Brun, Brianna N; Mockler, Shelley R H; Laubscher, Katie M et al. (2017) Comparison of brain MRI findings with language and motor function in the dystroglycanopathies. Neurology 88:623-629 |
| Carlson, Courtney R; McGaughey, Steven D; Eskuri, Jamie M et al. (2017) Illness-associated muscle weakness in dystroglycanopathies. Neurology 89:2374-2380 |
| Donkervoort, Sandra; Chan, Sophelia H S; Hayes, Leslie H et al. (2017) Cytoplasmic body pathology in severe ACTA1-related myopathy in the absence of typical nemaline rods. Neuromuscul Disord 27:531-536 |
| Wilson, Kristin; Faelan, Crystal; Patterson-Kane, Janet C et al. (2017) Duchenne and Becker Muscular Dystrophies: A Review of Animal Models, Clinical End Points, and Biomarker Quantification. Toxicol Pathol 45:961-976 |
Showing the most recent 10 out of 97 publications
